Format

Send to

Choose Destination
World J Gastroenterol. 2010 Nov 21;16(43):5518-22.

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.

Author information

1
Division of Hematology and Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, San Antonio, TX 78229, United States. wangy5@uthscsa.edu

Abstract

A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.

PMID:
21086573
PMCID:
PMC2988248
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center